Warts – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Warts – Pipeline Review, H2 2018’, provides an overview of the Warts pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Warts, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Warts and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Warts

– The report reviews pipeline therapeutics for Warts by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Warts therapeutics and enlists all their major and minor projects

– The report assesses Warts therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Warts

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Warts

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aclaris Therapeutics Inc

Agilvax Inc

BioMAS Ltd

Cadila Healthcare Ltd

Cutanea Life Sciences Inc

Cytovation AS

G&E Corp

Genetic Immunity Inc

Laboratories Ojer Pharma SL

LEO Pharma A/S

Maruho Co Ltd

Nielsen Biosciences Inc

Novan Inc

Novartis AG

Pfizer Inc

Promius Pharma LLC

RXi Pharmaceuticals Corp

Tamir Biotechnology Inc

Vaxart Inc

Verrica Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Warts - Overview

Warts - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Warts - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Warts - Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Agilvax Inc

BioMAS Ltd

Cadila Healthcare Ltd

Cutanea Life Sciences Inc

Cytovation AS

G&E Corp

Genetic Immunity Inc

Laboratories Ojer Pharma SL

LEO Pharma A/S

Maruho Co Ltd

Nielsen Biosciences Inc

Novan Inc

Novartis AG

Pfizer Inc

Promius Pharma LLC

RXi Pharmaceuticals Corp

Tamir Biotechnology Inc

Vaxart Inc

Verrica Pharmaceuticals Inc

Warts - Drug Profiles

(digoxin + furosemide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

854-A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Albicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AS-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AX-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Condyloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CyPep-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DFD-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FIT-039 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

furosemide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human papillomavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HupaDerm - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydrogen peroxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imiquimod SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ingenol mebutate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LFX-453 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omiganan pentahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pefcalcitol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

povidone iodine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranpirnase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RKP-00156 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Samcyprone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-206 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRT-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teslexivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VP-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Warts - Dormant Projects

Warts - Discontinued Products

Warts - Product Development Milestones

Featured News & Press Releases

Jun 04, 2018: Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir for the Treatment of Condyloma

May 18, 2018: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone for the Treatment of Common Warts

Apr 04, 2018: RXi Pharmaceuticals to Present on Samcyprone at the International Investigative Dermatology Conference

Mar 19, 2018: Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts

Jan 08, 2018: Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts

Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts

Sep 06, 2017: RXi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts

Jun 29, 2017: Aclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts

Apr 26, 2017: Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution

Mar 02, 2017: Novan's Phase 2 Results with SB206 to be Presented at 2017 AAD Annual Meeting

Mar 01, 2017: Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference

Nov 29, 2016: Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206

Aug 18, 2016: Aclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts

Jul 30, 2016: Cytovation granted EU patent for its lead product, CyPep-1, for the treatment of cutaneous warts

Jul 21, 2016: RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Warts, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Warts – Pipeline by Aclaris Therapeutics Inc, H2 2018

Warts – Pipeline by Agilvax Inc, H2 2018

Warts – Pipeline by BioMAS Ltd, H2 2018

Warts – Pipeline by Cadila Healthcare Ltd, H2 2018

Warts – Pipeline by Cutanea Life Sciences Inc, H2 2018

Warts – Pipeline by Cytovation AS, H2 2018

Warts – Pipeline by G&E Corp, H2 2018

Warts – Pipeline by Genetic Immunity Inc, H2 2018

Warts – Pipeline by Laboratories Ojer Pharma SL, H2 2018

Warts – Pipeline by LEO Pharma A/S, H2 2018

Warts – Pipeline by Maruho Co Ltd, H2 2018

Warts – Pipeline by Nielsen Biosciences Inc, H2 2018

Warts – Pipeline by Novan Inc, H2 2018

Warts – Pipeline by Novartis AG, H2 2018

Warts – Pipeline by Pfizer Inc, H2 2018

Warts – Pipeline by Promius Pharma LLC, H2 2018

Warts – Pipeline by RXi Pharmaceuticals Corp, H2 2018

Warts – Pipeline by Tamir Biotechnology Inc, H2 2018

Warts – Pipeline by Vaxart Inc, H2 2018

Warts – Pipeline by Verrica Pharmaceuticals Inc, H2 2018

Warts – Dormant Projects, H2 2018

Warts – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Warts, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports